Eyenovia Business Development and Partners

We envision the Optejet® being utilized for additional applications and drug therapies. Reduction in systemic exposure and toxicity with Optejet’s microdosing, compared to a traditional eyedropper, could mean a better tolerability and safety profile than existing topical treatments. For therapies where adherence is vital to treatment success, the Optejet can assist with patient compliance.

We believe our technology platform improves the therapeutic profile of new and existing drug solutions. We believe the Optejet can improve the therapeutic profile of many new and existing drug products. The Optejet device has patent protection until 2041.

For Future Licensing Opportunities